CYAD-211 Immunotherapy for Multiple Myeloma
(IMMUNICY-1 Trial)
Trial Summary
What is the purpose of this trial?
The purpose of the IMMUNICY-1 study is to assess the safety, activity and cell kinetics of CYAD-211 in adults with relapsed or refractory multiple myeloma after a lymphodepletion regimen with fludarabine and/or cyclophosphamide
Will I have to stop taking my current medications?
The trial requires that you stop any prior systemic therapy for multiple myeloma at least 14 days before starting the preconditioning chemotherapy.
What data supports the effectiveness of the treatment CYAD-211 for multiple myeloma?
Is CYAD-211 immunotherapy generally safe for humans?
Immunotherapy treatments like CYAD-211, which involve CAR T cells, have shown manageable safety profiles in clinical trials for multiple myeloma. Common side effects include cytokine release syndrome (a reaction where the immune system releases too many proteins into the blood too quickly) and neurotoxicity (nerve damage), but these are often mild and can be managed with medications.678910
How is the CYAD-211 treatment different from other treatments for multiple myeloma?
CYAD-211 is a type of CAR T-cell therapy, which is a form of immunotherapy that uses genetically engineered T-cells to target and destroy cancer cells. This approach is unique because it involves modifying a patient's own immune cells to specifically attack multiple myeloma cells, potentially offering a more targeted and effective treatment compared to traditional therapies.2341112
Eligibility Criteria
This trial is for adults with multiple myeloma that has come back or hasn't responded to at least two treatments, including IMiD and PIs. Participants must have measurable disease, be in decent physical shape (ECOG ≤2), and have good organ function. They can't join if they've had recent cancer treatment, CNS tumor involvement, a stem cell transplant too close to the study start date, or no response to previous BCMA-targeted therapy.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Preconditioning Chemotherapy
Participants receive a non-myeloablative preconditioning chemotherapy regimen with fludarabine and/or cyclophosphamide
Treatment
Participants receive an infusion of CYAD-211 (anti-BCMA CAR-T) cells
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- CYAD-211
Find a Clinic Near You
Who Is Running the Clinical Trial?
Celyad Oncology SA
Lead Sponsor